IPO registrations (S-1, F-1) · Registrants

MADRIGAL PHARMACEUTICALS, INC.

SEC CIK
1157601 · filings on EDGAR ↗
Name on the registration
SYNTA PHARMACEUTICALS CORP
Former names
SYNTA PHARMACEUTICALS CORP (2002–2016)
Registration
Form S-1, first filed 2005-01-18, last 2007-02-05; 2 initial registrations, 8 amendments
Outcome
Final prospectus filed 2007-02-07; declared effective 2007-02-05; withdrawal requested 2005-06-13
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, West Conshohocken, PA
Ticker
MDGL (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
MADRIGAL PHARMACEUTICALS, INC. on the corporate pages

Offering terms

Proposed price range
$14.00–$16.00 per share (S-1/A filed 2007-02-05)
Final price
$10.00 per share, below the range (424B4 filed 2007-02-07, an initial public offering)
Shares sold
5,000,000
Gross proceeds
$50,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol SNTA
Lead underwriters
Bear Stearns (2,000,000 shares)
Syndicate
Lehman Brothers (2,000,000); Lazard (750,000); Montgomery & Co., LLC (250,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 15

FiledFormWhat it isName as filedEDGAR
2005-01-18S-1S-1 (registration)SYNTA PHARMACEUTICALS CORP0001047469-05-001033 ↗
2005-02-23S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-05-004481 ↗
2005-03-17S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-05-006934 ↗
2005-04-22S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-05-010966 ↗
2005-04-29S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-05-012454 ↗
2005-06-13RWRW (withdrawal request)SYNTA PHARMACEUTICALS CORP0001047469-05-017134 ↗
2006-11-22S-1S-1 (registration)SYNTA PHARMACEUTICALS CORP0001047469-06-014434 ↗
2006-12-01S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-06-014679 ↗
2007-01-04S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-07-000036 ↗
2007-01-23S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-07-000315 ↗
2007-02-05S-1/AS-1/A (amendment)SYNTA PHARMACEUTICALS CORP0001047469-07-000597 ↗
2007-02-05EFFECTEFFECT (declared effective)SYNTA PHARMACEUTICALS CORP9999999995-07-000448 ↗
2007-02-06EFFECTEFFECT (declared effective)SYNTA PHARMACEUTICALS CORP9999999995-07-000475 ↗
2007-02-07424B4424B4 (final prospectus)SYNTA PHARMACEUTICALS CORP0001047469-07-000713 ↗
2008-08-28EFFECTEFFECT (declared effective)SYNTA PHARMACEUTICALS CORP9999999995-08-002664 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2007-02-05S-1/Aregistration statement$14.00–$16.00$15.006,000,000$90,000,000Nasdaq SNTA4primary document; range, price sentence, shares headline, proceeds computed, cover names 4document ↗
2007-02-07424B4final prospectus$10.005,000,000$50,000,000Nasdaq SNTA4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Bahcall Safi RDirector,OfficerPresident and CEO262007–2014
Barsoum James GOfficerSr. VP, Research42007–2009
CAXTON CORPTenPercentOwner22007
Chadwick Jeremy GOfficerSr. VP, Pgm Mgmt and Clin Ops; Sr. VP, Program Mgmt and Ops72007–2010
Chen Lan BoDirector; Director,TenPercentOwner92007–2013
Chen Lin HueyTenPercentOwner62007–2010
CxSynta LLCTenPercentOwner22007
Ehrlich Keith SOfficerVP, Fin. and Admin., CFO132007–2014
Folkman JudahDirector22007
Gollust Keith RDirector372007–2022
Jacobson Eric WOfficerSr. VP, Research and CMO52007–2009
Kovner BruceDirector,TenPercentOwner522007–2015
Koya KeizoOfficerSr. VP, Drug Development112007–2012
REARDON WILLIAM SDirector112007–2015
Rieder Wendy EOfficerFormer SVP, Gen. Counsel; SVP, Gen. Counsel; VP, IP and Legal, Gen. Counsel172007–2016
Williams Martin DOfficerSr. VP, Business Dev., CBO52007–2008
WILSON ROBERT NDirector172007–2015
BAILEY MICHAEL POfficerSr. VP, Chief Comm. Officer52008–2010
Vukovic VojoOfficerSVP, Chief Medical Officer142009–2015
KUFE DONALD WDirector92010–2015
Singh AmarOfficerSr. VP, Business & Comm. Dvp.; Sr. VP, Chief Business Officer72010–2014
Ramachandra SumantOfficerPresident, R&D22013
Bernitz Steven BOfficerSVP, Corporate Development22013
McMahon ArthurOfficerSVP, Human Resources; SVP, People Operations32014–2015
FRIEDMAN PAUL ADirector; Director,OfficerChief Executive Officer292014–2026
Whitaker Anne ClemDirector,OfficerPresident and CEO32014–2015
Schneebaum Marc ROfficerChief Financial Officer; SVP and CFO122014–2021
Schor ChenDirector,Officer; OfficerExecutive VP and COO; Former President and CEO; President and CEO62014–2016
Morenstein Scott DDirector32015–2016
BAY CITY CAPITAL FUND IV CO INVESMENT FUND LPDirector,TenPercentOwner; TenPercentOwner72016–2021
Bay City Capital Fund IV, L.P.Director,TenPercentOwner; TenPercentOwner72016–2021
BAY CITY CAPITAL LLCDirector,TenPercentOwner; TenPercentOwner82016–2021
Bay City Capital Management IV LLCDirector,TenPercentOwner; TenPercentOwner72016–2021
CRAVES FRED BDirector; Director,TenPercentOwner292016–2025
Taub RebeccaDirector; Director,Officer; Director,Officer,TenPercentOwnerChief Medical Officer, EVP R&D; President of R&D; Pres., R&D, and CMO; See Remarks292016–2026
BATE KENNETHDirector162016–2025
MILLIGAN DAVID VDirector132016–2022
Levy Richard SDirector242016–2026
Lynch Brian JosephOfficerSee Remarks; SVP and General Councel; SVP and General Counsel132019–2024
Daly James MDirector112019–2026
Sukhija RemyOfficerChief Commercial Officer; SVP and Chief Comm'l Officer52020–2023
Howarth Alex G.OfficerChief Financial Officer72021–2024
Waltermire Robert E.OfficerSenior VP, Chief Pharma Dev.162021–2025
667, L.P.Director142023–2026
Baker Bros. Advisors (GP) LLCDirector142023–2026
BAKER BROS. ADVISORS LPDirector152023–2026
Baker Brothers Life Sciences LPDirector142023–2026
BAKER FELIXDirector142023–2026
BAKER JULIANDirector142023–2026
Cheong RaymondDirector12023
Sibold William JohnDirector,OfficerPresident and CEO142023–2026
Huntsman CaroleOfficerChief Commercial Officer102023–2026
Dier MardiOfficerEVP and CFO; SVP and CFO72024–2026
Kelley Shannon TOfficerGeneral Counsel92024–2026
FOUSE JACQUALYN ADirector42025–2026
Soergel DavidOfficerChief Medical Officer52025–2026
Brennan Daniel J.Director32025–2026
Thakkar RitaOfficerChief Accounting Officer22026
REED JOHN CDirector22026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2017-07-05MADRIGAL PHARMACEUTICALS, INC.Pharmaceuticals$35,000,018$35,000,01851

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationMadrigal Pharmaceuticals, Inc.PAState business registriesname and state
Business registrationMadrigal Pharmaceuticals, Inc.PAState business registriesname and state
Business registrationMadrigal Pharmaceuticals, Inc.PAState business registriesname and state
Business registrationMADRIGAL PHARMACEUTICALS, INCPAState business registriesname and state
Business registrationMADRIGAL PHARMACEUTICALS, INCPAState business registriesname and state
Business registrationMADRIGAL PHARMACEUTICALS, INCPAState business registriesname and state
Business registrationMADRIGAL PHARMACEUTICALS, INCPAState business registriesname and state
Business registrationMADRIGAL PHARMACEUTICALS, INC.PAState business registriesname and state
Plan sponsorMADRIGAL PHARMACEUTICALS, INC.PAForm 5500 (employee benefit plans)name and state
Federal award recipientMADRIGAL PHARMACEUTICALS, INCPAFederal spending (USAspending)name and state
Form D issuerMadrigal Pharmaceuticals, Inc.PAForm D private offeringsname and state
Form D issuerMADRIGAL PHARMACEUTICALS, INC.PAForm D private offeringsCIK (EXACT)
Lobbying clientMADRIGAL PHARMACEUTICALSPAFederal lobbying (LDA)name and state
Lobbying clientMADRIGAL PHARMACEUTICALS, INC.PAFederal lobbying (LDA)name and state
Lobbying clientMADRIGAL PHARMACEUTICALS, INC.PAFederal lobbying (LDA)name and state
Lobbying clientMADRIGAL PHARMACEUTICALS, INC.PAFederal lobbying (LDA)name and state
Lobbying clientMADRIGAL PHARMACEUTICALS, INC.PAFederal lobbying (LDA)name and state
Lobbying registrantMADRIGAL PHARMACEUTICALS, INC.PAFederal lobbying (LDA)name and state
Paying companyMadrigal PharmaceuticalsPAOpen Payments (drug and device company payments)name and state
Patent assigneeMadrigal Pharmaceuticals, Inc.PAPatents (USPTO)name and state
SEC filerMADRIGAL PHARMACEUTICALS, INC.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerMadrigal Pharmaceuticals, Inc.PATrademarks (USPTO)name and state

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, PA first:

More with this interest.

In other datasets, the same topic (Health) in PA:

Interests: Pharmaceutical Preparations · Health